Eisai Inc. on Thursday celebrated the official opening of its new headquarters on the ON3 campus in Nutley — the Eisai US hhceco Center.
The new 332,800-square-foot-facility brings approximately 800 jobs to the area and, at full capacity, will accommodate 1,300 employees.
The center will expand the diverse and powerful life sciences community in New Jersey, bringing a dedicated commitment to addressing medical challenges in cancer, Alzheimer’s disease and other neurological diseases. It also aims to advance the company’s human health care mission, which has a strong structure of collaborative relationships that further its work to address the needs of people throughout their lives.
Eisai brought together officials and executives as well as Gov. Phil Murphy for a ribbon-cutting event that highlighted the positive impact of this new location.
Eisai’s global CEO, Haruo Naito, highlighted how the company is expanding its longstanding human health care — or hhc — mission to address health care’s most pressing challenges, based on the concept of an ecosystem model in which organizations share technologies, exchange values and grow together to deliver health-related solutions that matter to people and contribute to society.
“We’re excited to welcome the new Eisai US hhceco Center to our very own Nutley, New Jersey. This new collaborative and innovative center will bring hundreds of jobs to our state,” Murphy stated. “New Jersey has become a hub for innovation in many industries, and Eisai’s extraordinary innovative research that will take place here will contribute to life-changing scientific and medical solutions for people living with cancer, Alzheimer’s disease and other neurodegenerative diseases.”
The center is located so it can foster existing collaborations and develop important new relationships. Additionally, the building offers a dynamic, technologically advanced environment that further enables the company’s commitment to innovation.
“The official grand opening of the Eisai US hhceco Center reinforces our 30-year commitment to New Jersey and signifies the beginning of a new chapter as we establish an ecosystem platform to collaborate with industry, government, medical organizations and the community to deliver breakthrough medicines and new solutions that alleviate the health concerns of people so they can live healthier and more fulfilling lives,” said Ivan Cheung, chairman & CEO of Eisai Inc., global Alzheimer’s disease officer, and senior corporate officer, Eisai Co. Ltd. “We are so honored to celebrate this important milestone for our company with such an esteemed group of dignitaries and contributors to the New Jersey life sciences community. “
